Abstract:
OBJECTIVE:The objective of this study was to describe the economic burden to managed care associated with failure of selective serotonin reuptake inhibitor (SSRI) therapy in terms of direct medical costs. METHODS:A retrospective analysis of the PharMetrics database, a national managed care medical and pharmacy claims dataset of 1.9 million major depressive disorder patients between January 2003 and June 2005 was conducted. A pre-post comparison of annual medical cost increases following new SSRI treatment was performed and differences in mean cost increases for the SSRI-failure versus non-failure groups were calculated using t-tests and confirmed using multivariate linear regression. RESULTS:The percentage of subjects with likely SSRI treatment failure was 30.7% (n=2,595). The two groups were statistically similar (p>0.05) in age, gender distribution and insurance status. The mean increase in total direct medical costs was $6,489 versus $3,257 for the SSRI treatment failure and non-failure cohorts, respectively. The major components of these cost increases were outpatient cost ($2,579 vs. $1,309) and inpatient cost ($2,862 vs. $1,532), between the SSRI treatment failure and non-failure cohorts, respectively. All differences remained statistically significant at p<0.001, even after controlling for potential confounders. CONCLUSIONS:This descriptive study found that increased costs of major depressive disorder are substantial following the onset of a new SSRI treatment episode and significantly higher among patients with likely SSRI treatment failure.
journal_name
J Med Econjournal_title
Journal of medical economicsauthors
Balkrishnan R,Joish VN,Yang T,Jayawant SS,Mullins CDdoi
10.3111/13696990802522339subject
Has Abstractpub_date
2008-01-01 00:00:00pages
601-10issue
4eissn
1369-6998issn
1941-837Xjournal_volume
11pub_type
杂志文章abstract:OBJECTIVE:Systemic lupus erythematosus is a complex autoimmune disease, most frequently affecting women of childbearing age. Women with lupus are at increased risk of pregnancy complications that are exacerbated by active disease. Despite this, their use of medications and hospital resources has not been extensively st...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2015.1066796
更新日期:2015-01-01 00:00:00
abstract:OBJECTIVE:To assess the cost-effectiveness of panitumumab in combination with mFOLFOX6 (oxaliplatin, 5-fluorouracil, and leucovorin) vs bevacizumab in combination with mFOLFOX6 as first-line treatment of patients with wild-type RAS metastatic colorectal cancer (mCRC) in Spain. METHODS:A semi-Markov model was developed...
journal_title:Journal of medical economics
pub_type: 杂志文章,随机对照试验
doi:10.1080/13696998.2017.1285780
更新日期:2017-06-01 00:00:00
abstract:OBJECTIVES:Atazanavir (ATV) and darunavir (DRV) are protease inhibitors approved for HIV treatment in combination with ritonavir (/r). The objectives of this study were to compare persistence (time to treatment discontinuation/modification), adherence, and healthcare costs among patients with human immunodeficiency vir...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2015.1128942
更新日期:2016-01-01 00:00:00
abstract:OBJECTIVE:To characterize patient and physician satisfaction with current standard-of-care botulinum toxin treatment regimens for symptom control in patients with post-stroke spasticity using structured interviews with patients and physicians. RESEARCH DESIGN AND METHODS:Two cross-sectional surveys were conducted in C...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2014.925462
更新日期:2014-09-01 00:00:00
abstract:OBJECTIVE:To assess the economic impact of initial and repeat hospitalizations associated with acute coronary syndrome (ACS) over 1 year (2009). DESIGN AND METHODS:National- and state-level data on length of stay (LOS) and related charges for ACS-associated hospital admissions were assessed using two Healthcare Utiliz...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2014.885907
更新日期:2014-03-01 00:00:00
abstract:AIMS:This study analyzed discrepancies in the quantity of medical services supplied by physicians under different payment systems for patients with different health statuses and illnesses by means of a field experiment. METHODS:Based on the laboratory experiment of Heike Hennig-Schmidt, we designed a field experiment ...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2018.1539399
更新日期:2019-01-01 00:00:00
abstract:OBJECTIVE:The past few decades have been marked by a bold increase in national health spending across the globe. Rather successful health reforms in leading emerging markets such as BRICS reveal a reshaping of their medical care-related expenditures. There is a scarcity of evidence explaining differences in long-term m...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2015.1093493
更新日期:2016-01-01 00:00:00
abstract:OBJECTIVE:Abdominal paracentesis is commonly performed for diagnostic, therapeutic, and palliative indications, but the use of ultrasound guidance for these procedures is relatively recent, variable, and not well documented. A retrospective database analysis of abdominal paracentesis procedures was performed to determi...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2011.628723
更新日期:2012-01-01 00:00:00
abstract:AIMS:Improvements in information technology have granted the recent development of rapid, cloud-enabled, onsite laboratory testing for rheumatoid arthritis (RA). This study aims to quantify the value to payers of such technologies. MATERIALS AND METHODS:To calculate the value of rapid, cloud-enabled, onsite laboratory...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2018.1502191
更新日期:2018-11-01 00:00:00
abstract:PURPOSE:To evaluate the insulin wastage and associated acquisition costs when switching from individual patient supply (IPS) of 3-mL pens of rapid-acting insulin (RAI) aspart to floor stock (FS) dispensing of 3-mL vials of RAI lispro, and with conversion from IPS of 3-mL pens to centralized unit dose (CUD) of 10-mL via...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2017.1288126
更新日期:2017-05-01 00:00:00
abstract:AIMS:The prevalence of atrial fibrillation (AF) has increased over the past years due to aging of the population, and healthcare costs associated with AF reflect a significant financial burden. The aim of this study was to explore predictors for the real-world AF-related in-hospital costs in patients that recently init...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2017.1363766
更新日期:2017-12-01 00:00:00
abstract:AIM:Disease-modifying therapies (DMTs) impact the natural history of relapsing forms of multiple sclerosis (RRMS) by reducing annual relapse rates and slowing disability progression. The effect of DMTs on indirect costs has not been consistently explored in cost-effectiveness studies thus far. The value to patients of ...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2017.1357564
更新日期:2017-10-01 00:00:00
abstract::Background: Adults admitted to hospital with community-acquired pneumonia (CAP) impose significant burden upon limited hospital resources. To achieve early response and possibly early discharge, thus reducing hospital expenditure, the choice of initial antibiotic therapy is pivotal.Methods: A cost-consequences model w...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2019.1688819
更新日期:2020-02-01 00:00:00
abstract:OBJECTIVES:To describe the changes in resource utilization in seven European countries (Germany, Greece, Portugal, Romania, Sweden, Spain, and Turkey) and direct costs in four European countries (Germany, Spain, Sweden, and Greece) over the first 12 months of insulin treatment in patients with type 2 diabetes mellitus ...
journal_title:Journal of medical economics
pub_type: 杂志文章,多中心研究
doi:10.3111/13696998.2013.812040
更新日期:2013-08-01 00:00:00
abstract::Background: Guidelines recommend febrile neutropenia (FN) prophylaxis following myelotoxic chemotherapy with either daily injections of filgrastim (Neupogen®) or biosimilar filgrastim-sndz (Zarzio/Zarxio®), single-injection pegfilgrastim (Neulasta®), or pegfilgrastim administered through an on-body injector (PEG-OBI; ...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2019.1658591
更新日期:2020-01-01 00:00:00
abstract:BACKGROUND:Approximately 20-30% of Canadians suffer from chronic pain. Guidelines for the management of chronic pain support the use of controlled-release (CR) opioids to treat chronic pain. Although effective in managing chronic pain, oxycodone is associated with high rates of opioid-induced constipation (OIC). The co...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2015.1116992
更新日期:2016-01-01 00:00:00
abstract:OBJECTIVES:To describe treatment patterns and healthcare burden among individuals with suspected pulmonary arterial hypertension (PAH), as identified through a practice guideline-based healthcare claims algorithm. METHODS:Adults with evidence of PAH from 1 January 2004 (commercial and Medicaid) or 1 July 2006 (Medicar...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2012.690801
更新日期:2012-01-01 00:00:00
abstract:BACKGROUND:A Phase-3 study of defibrotide compared with historical controls demonstrated a 23% improvement in 100-day survival post-hematopoietic stem cell transplantation (HSCT) among patients with veno-occlusive disease with multi-organ dysfunction (VOD with MOD). AIM:To estimate the budget impact and cost-effective...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2016.1275652
更新日期:2017-05-01 00:00:00
abstract:OBJECTIVES:To evaluate the economic burden of herpes zoster (HZ) on the US healthcare system among an immunocompetent population. METHODS:Claims data from the MarketScan Research databases for 2008-2011 were extracted to determine the incremental healthcare resource utilization (RU) and direct medical costs associated...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2016.1187150
更新日期:2016-10-01 00:00:00
abstract::Aims: Nocturia (getting up at night to urinate, where each urination being followed by sleep or intention to sleep) is a bothersome symptom with potentially negative consequences for individual health and daytime functioning. This study assessed the burden of nocturia in the workplace by investigating associations bet...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2020.1767631
更新日期:2020-09-01 00:00:00
abstract:AIMS:Tuberous sclerosis complex (TSC) is a multi-organ autosomal-dominant, genetic disorder with incomplete penetrance. The multiple manifestations of TSC and impacts to numerous organ systems represent significant disease, healthcare, and treatment burden. The economic and employment burden of the disease on individua...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2018.1487447
更新日期:2018-10-01 00:00:00
abstract:OBJECTIVES:Non-severe nocturnal hypoglycemic events (NSNHEs) may have a major impact on patients. The objective was to determine how NSNHEs affect diabetes management, sleep quality, functioning, and to assess if these impacts differ by diabetes type or country. METHODS:An internet survey to adults with diabetes in th...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2011.624144
更新日期:2012-01-01 00:00:00
abstract:OBJECTIVE:To estimate health-related quality of life (HRQoL) in non-growth hormone deficient (GHD) small for gestational age (SGA) children before and after growth hormone (GH) treatment to adult height (AH). METHODS:This was a multicentre, two-arm trial. Following an initial 2-year double-blind study period, patients...
journal_title:Journal of medical economics
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.3111/13696998.2010.484323
更新日期:2010-01-01 00:00:00
abstract::Objectives: To describe the clinical characteristics, treatment pattern, and medical costs associated with metastatic castration-resistant prostate cancer (mCRPC) in Chinese patients. Methods: This retrospective study identified a group of patients with newly-developed mCRPC from 2012 to 2016 to extract information fr...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2019.1600524
更新日期:2019-08-01 00:00:00
abstract:BACKGROUND:Neuroblastoma (NB) is notorious in childhood cancer because of its high incidence and poor prognosis. The Children's Oncology Group reported that the 3-year OS in the high-risk (HR) group is 50%, and the HR-NB with bone marrow metastasis in our center is 43.1%. Thousands of families in China suffer from the ...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2020.1786392
更新日期:2020-09-01 00:00:00
abstract:OBJECTIVE:To estimate the economic implications of introducing dabigatran etexilate ('dabigatran') for anti-coagulation therapy in Danish patients with non-valvular atrial fibrillation based on results of the RE-LY trial. METHODS:The lifetime cost and outcomes of dabigatran and warfarin were estimated using a previous...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2012.673525
更新日期:2012-01-01 00:00:00
abstract:OBJECTIVE:To assess the cost-effectiveness (CE) of the originator follitropin-α (Gonal-F) in patients undergoing a medically assisted reproduction (MAR) program in comparison to its biosimilars Bemfola and Ovaleap in a French context. METHODS:A CE model was developed for France with a National Health Service (NHS) per...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2018.1551226
更新日期:2018-11-21 00:00:00
abstract:OBJECTIVE:Compare long-term costs and outcomes of lurasidone to aripiprazole among adults with schizophrenia in the US who previously failed ≥1 atypical antipsychotic (olanzapine, risperidone, quetiapine, or ziprasidone) based on an indirect comparison of outcomes data from clinical trials. METHODS:A 5-year Markov coh...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2013.807813
更新日期:2013-07-01 00:00:00
abstract::Aims: This article aimed to examine the cost-effectiveness of rivaroxaban in comparison to warfarin for stroke prevention in Japanese patients with non-valvular atrial fibrillation (NVAF), from a public healthcare payer's perspective.Materials and methods: Baseline event risks were obtained from the J-ROCKET AF trial ...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2019.1688821
更新日期:2020-03-01 00:00:00
abstract:BACKGROUND:Many countries have various requirements for local economic analyses to assess the value of a new health technology and/or to secure reimbursement. This study presents a case study of an economic model developed to assess the cost-effectiveness of posaconazole vs standard azole therapy (fluconazole/itraconaz...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2012.761633
更新日期:2013-01-01 00:00:00